✦ LIBER ✦

Two-year observation of the clinical efficacy in treating chronic hepatitis B patients with Ganxian recipe and lamivudine

✍ Scribed by Shen Wei-sheng; Yang Hong-zhi; Hong Qi; Zhang Yong-qiang; Xie He-ping; Bian Zhuang

Publisher: Chinese Association of Traditional and Western Medicine
Year: 2005
Tongue: English
Weight: 505 KB
Volume: 11
Category: Article
ISSN: 1672-0415
DOI: 10.1007/bf02835740

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical and immunological efficacy of i

Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B

✍ Anja Dahmen; Sabine Herzog-Hauff; Wulf O. Böcher; Peter R. Galle; Hanns F. Löhr 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 1 views

## Abstract To evaluate therapeutic immunostimulation nine chronic hepatitis B patients received six monthly intradermal vaccinations with HBsAg in combination with daily lamivudine. Another five patients received six doses of the vaccine and daily lamivudine together with daily Interleukin‐2 (IL‐2

Efficacy of entecavir in patients with c

Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone

✍ Ju Hyun Shim; Dong Jin Suh; Kang Mo Kim; Young-Suk Lim; Han Chu Lee; Young-Hwa C 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 1 views

Entecavir (ETV) is currently recommended as a rescue therapy purely for adefovir (ADV)resistant chronic hepatitis B virus (HBV) infections. We evaluated the efficacy of ETV in patients who were resistant to lamivudine (LAM)/ADV sequential therapy and in those resistant to LAM monotherapy. Fifty LAM/

Favorable efficacy of long-term lamivudi

Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: An 8-year follow-up study

✍ Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Hitomi Sezaki; Tetsuya Hosaka; T 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 1 views

## Abstract The long‐term efficacy of lamivudine therapy in patients with hepatitis B virus (HBV) infection is still not clear. In this study, 20 non‐cirrhotic Japanese patients infected with HBV received lamivudine therapy for more than 1 year and were followed for a median period of 8.5 years (ra

Mutations associated with the therapeuti

Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis

✍ Kazuyoshi Ohkawa; Tetsuo Takehara; Michio Kato; Aimi Kanada; Matsuo Deguchi; Mas 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB

## Abstract Factors influencing the therapeutic efficacy of adefovir dipivoxil added to continuing lamivudine have not been elucidated in lamivudine‐resistant patients with type B chronic hepatitis. The viral mutations influencing the efficacy of treatment with adefovir dipivoxil were investigated

Efficacy of lamivudine in patients with

Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB

✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Efficacy of adefovir add-on lamivudine r

Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B

✍ Han Jak Ryu; Jung Min Lee; Sang Hoon Ahn; Do Young Kim; Myoung Ha Lee; Kwang-Hyu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Abstract No study has reported on the comparative effect of adefovir (ADV) add‐on lamivudine (LAM) versus switching to entecavir (ETV) in LAM‐resistant patients with chronic hepatitis B. From October 2007 to September 2008, 92 consecutive LAM‐resistant patients were enrolled (47 LAM + ADV and 45